Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Lasers Med Sci. 2024 Jun 1;39(1):146. doi: 10.1007/s10103-024-04098-9.
Previous clinical studies have shown that pulsed dye laser (PDL) and intense pulsed light (IPL) are effective for treating erythematotelangiectatic rosacea(ETR). This article aims to compare the efficacy and safety of PDL and IPL at three different wavelength bands (broad-band, single-narrow-band, and dual-narrow-band) in treating ETR. Sixty subjects with ETR were randomly categorized into four groups and received one of the following laser treatments: PDL (595 nm), IPL with Delicate Pulse Light (DPL, 500-600 nm), IPL with M22 590 (590-1200 nm), or IPL with M22 vascular filter (530-650 nm and 900-1200 nm). Four treatment sessions were administered at 4-week intervals, with one follow-up session 4 weeks after the final treatment. The efficacy of the four lasers was evaluated by comparing the clinical symptom score, total effective rate, VISIA red area absolute score, and RosaQoL score before and after treatment. The safety was evaluated by comparing adverse reactions such as pain, purpura, erythematous edema, and blister. All 60 subjects completed the study. Within-group effects showed that the clinical symptom score, VISIA red area absolute score, and RosaQoL score of all four groups were significantly reduced compared to before treatment (p < 0.001). Between-group effects showed no statistically significant difference among the four laser groups. Safety analysis showed that all four lasers were safe, but the incidence of blister was higher in the M22 vascular group. Nonpurpurogenic PDL, DPL, M22 590, and M22 vascular were equally effective in treating ETR and were well-tolerated. ClinicalTrial.gov Identifier: NCT05360251.
先前的临床研究表明,脉冲染料激光(PDL)和强脉冲光(IPL)对治疗红斑毛细血管扩张型酒渣鼻(ETR)有效。本文旨在比较 PDL 和 IPL 在三个不同波长波段(宽带、单窄带和双窄带)治疗 ETR 的疗效和安全性。60 例 ETR 患者随机分为四组,分别接受以下激光治疗之一:PDL(595nm)、具有精细脉冲光(DPL,500-600nm)的 IPL、具有 M22 590nm(590-1200nm)的 IPL 或具有 M22 血管滤光器(530-650nm 和 900-1200nm)的 IPL。四次治疗间隔 4 周,最后一次治疗后 4 周进行一次随访。通过比较治疗前后的临床症状评分、总有效率、VISIA 红色区域绝对评分和 RosaQoL 评分来评估四种激光的疗效。通过比较疼痛、瘀斑、红斑性水肿和水疱等不良反应来评估安全性。所有 60 例患者均完成了研究。组内效应显示,与治疗前相比,四组的临床症状评分、VISIA 红色区域绝对评分和 RosaQoL 评分均显著降低(p<0.001)。组间效应显示,四组激光之间无统计学差异。安全性分析显示,四种激光均安全,但 M22 血管组水疱发生率较高。非紫癜性 PDL、DPL、M22 590 和 M22 血管对 ETR 的治疗效果相同,且耐受性良好。ClinicalTrial.gov 标识符:NCT05360251。